A first-hand report from MedShadow Foundation describes PepMed 2026, the American Academy of Peptide Medicine's inaugural meeting, as an industry gathering long on enthusiasm for expanded peptide access and short on the evidence that would justify it. The reporter, a former postdoctoral scientist with a Ph.D. in medicinal chemistry focused on peptides, attended the one-hour press window on September 17 at a Washington, DC hotel alongside roughly 300 doctors, practitioners, entrepreneurs and lawmakers.

The compounds at issue sit on the FDA's Category 2 list, which flags substances over safety concerns including immunogenicity and missing human data. They include BPC-157 and TB-500, marketed together as the "Wolverine stack," plus Thymosin alpha-1, Semax and GHK-Cu.

A regulatory door opening

In February 2026, Health Secretary Robert F. Kennedy Jr. said on a podcast that roughly 14 of the 19 Category 2 peptides would be moved back to Category 1, which would make them compoundable with a prescription. That plan has not been finalized, and none of those peptides can be legally compounded as of MedShadow's publication.

In July, the Pharmacy Compounding Advisory Committee reviewed seven of them and recommended adding all but emideltide to Category 1, against FDA staff's recommendation on all seven. The committee's advice is non-binding, and on October 14 the agency sent an interim access policy to the White House for review.

Twenty million doses, and what they do not show

AAPM chairman Lee Rosebush, a pharmacist and regulatory attorney, told the FDA in July that real-world data from five clinics and six manufacturers represented more than 20 million doses, with an adverse-event rate of less than 0.007%. Reported events were limited to injection-site lumps, rashes and similar hypersensitivity reactions.

MedShadow's reporter found the volume unconvincing as a safety argument. Most cited studies were in animals or dishes, the human trials generally ran under six months with fewer than 100 participants, and there appeared to be no standardized system ensuring adverse events were consistently monitored or reported.

The identity problem

The FDA has also criticized the absence of standard methods for characterizing these substances. The agency found at least two versions of products labeled BPC-157, acetate and free base, dispensed across five routes including injection, nasal spray, cream, capsule and suppository.

Different salt forms and routes are not interchangeable in pharmacology, and the agency argues that without consistent characterization it is hard to attribute either benefit or harm to the named compound.

Who is advising whom

The Washington Post reported in June that several recently added PCAC members had financial ties to the pharmaceutical and peptide industries. Rosebush dismissed the criticism, asking why oncologists on an oncology committee are not treated the same way.

Bottom line

The advocates have momentum: a sympathetic health secretary, a favorable advisory vote, and a policy sitting at the White House. What nobody at PepMed addressed, by MedShadow's account, is what incentive remains to fund rigorous trials once compounding pharmacies can supply these peptides at scale.